Silvan Turkcan
Stock Analyst at Citizens JMP
(0.37)
# 4,472
Out of 5,058 analysts
9
Total ratings
12.5%
Success rate
-24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Silvan Turkcan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AAPG Ascentage Pharma Group International | Initiated Coverage: Buy | $35 | $14.85 | +135.69% | 1 | Oct 13, 2026 | |
| CNTX Context Therapeutics | Reiterated: Buy | $3 | $0.2556 | +1,073.71% | 1 | Aug 6, 2026 | |
| IDYA IDEAYA Biosciences | Reiterated: Buy | $42 | $33.86 | +24.04% | 1 | Aug 6, 2026 | |
| CRSP CRISPR Therapeutics AG | Reiterated: Buy | $80 | $50.22 | +59.30% | 1 | Jul 22, 2026 | |
| FTH Faeth Therapeutics | Initiated Coverage: Buy | $51 | $20.00 | +155.00% | 1 | Jul 20, 2026 | |
| CELC Celcuity | Reiterated: Buy | $160 → $177 | $59.90 | +195.49% | 3 | Jul 15, 2026 | |
| HURA TuHURA Biosciences | Initiated Coverage: Buy | $9 | $1.76 | +411.36% | 1 | Apr 27, 2026 |
Ascentage Pharma Group International
Oct 13, 2026
Initiated Coverage: Buy
Price Target: $35
Current: $14.85
Upside: +135.69%
Context Therapeutics
Aug 6, 2026
Reiterated: Buy
Price Target: $3
Current: $0.2556
Upside: +1,073.71%
IDEAYA Biosciences
Aug 6, 2026
Reiterated: Buy
Price Target: $42
Current: $33.86
Upside: +24.04%
CRISPR Therapeutics AG
Jul 22, 2026
Reiterated: Buy
Price Target: $80
Current: $50.22
Upside: +59.30%
Faeth Therapeutics
Jul 20, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $20.00
Upside: +155.00%
Celcuity
Jul 15, 2026
Reiterated: Buy
Price Target: $160 → $177
Current: $59.90
Upside: +195.49%
TuHURA Biosciences
Apr 27, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $1.76
Upside: +411.36%